Intratumoral Gene Transfer of the Cytosine Deaminase Gene for the Treatment of Breast Cancer
One of the major limitations of conventional cancer chemotherapy is its lack of selectivity; there is cytotoxicity to both tumor cells and normal cells. Genetic prodrug activation therapy (GPAT) uses transcriptional differences between normal and neoplastic cells to drive the selective expression of a metabolic suicide gene able to convert a nontoxic prodrug into its toxic metabolite. Genetically modified cells that express the nonmammalian enzyme cytosine deaminase (CD) gene are able to convert the nontoxic prodrug 5-fluorocytosine (5-FC) to the toxic metabolite 5-fluorouracil (5-FU), which inhibits RNA and DNA synthesis during S-phase of the cell cycle (1 ,2 ). We have devised a transcriptionally targeted GPAT strategy in which expression of CD is restricted to ERBB2-expressing tumor cells. Exposure of CD-expressing cells to 5-FC should result in tumor-selective cell kill thereby sparing normal breast cells.
- Measurement of Reduced Glutathione Using High-Pressure Liquid Chromatography
- Prediction of the Biological Effect of Polymorphisms Within MicroRNA Binding Sites
- Selection of Cytochrome P450 Genes for Use in Prodrug Activation-Based Cancer Gene Therapy
- Medical Management of Hepatocellular Carcinoma
- Screening for Molecular Markers of Cervical Papillomavirus Infection: Overview of Methods and Their Clinical Implications
- Construction of P450-Expressing Tumor Cell Lines Using Retroviruses
- Practical Methods for Tissue Microarray Construction
- Generation and Screening of a Modular Human scFv Expression Library from Multiple Donors
- 微膠囊造粒技術(shù)在細(xì)胞移植,藥物和食品研究中的成功應(yīng)用
- Clonality Detection of Expanded T-Cell Populations in Patients With Multiple Myeloma